Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company is a healthcare business focused on pharmaceuticals and listed on the NYSE as common equity under the ticker BMY. Through its biopharmaceutical operations, it is involved in the discovery, development, licensing, manufacture, marketing, distribution, and sale of medicines used in oncology, hematology, immunology, cardiovascular disease, neuroscience, and other therapeutic areas. Its portfolio includes products such as Opdivo, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Zeposia, Abecma, Sotyktu, Krazati, Cobenfy, Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel, Abraxane, and Augtyro. The company sells its products through wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb was formerly known as Bristol-Myers Company and is headquartered in Princeton, New Jersey.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-BMY
|
$46.43
|
-23.0% Downside
|
Overvalued
|
$62.96
|
4.4% Upside
|
Fair
|
Great
|
July 2, 2026
|
August 3, 2026
|
2.52
|
4.2%
|
July 30, 2026
|
16.9x
|
6.1x
|
2.5x
|
122.9 B
|
156.3 B
|
27.4%
|
99.8%
|
4.0
|
69.7%
|
163.7%
|
